NEW YORK (Reuters) – Allergan Plc (AGN.N) said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.
The Allergan logo is seen in this photo illustration November 23, 2015. REUTERS/Thomas White/Illustration/File Photo
The drugmaker announced earlier on Friday the acquisition of Bonti Inc, which makes a shorter-acting neurotoxin than Botox.
Allergan is also doubling its investment in direct-to-consumer ad spending and beefing up its sales force as companies like Revance…